209 related articles for article (PubMed ID: 34681614)
1. L-Type Amino Acid Transporter 1 Regulates Cancer Stemness and the Expression of Programmed Cell Death 1 Ligand 1 in Lung Cancer Cells.
Liu YH; Li YL; Shen HT; Chien PJ; Sheu GT; Wang BY; Chang WW
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681614
[TBL] [Abstract][Full Text] [Related]
2. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.
Maimaiti M; Sakamoto S; Yamada Y; Sugiura M; Rii J; Takeuchi N; Imamura Y; Furihata T; Ando K; Higuchi K; Xu M; Sazuka T; Nakamura K; Kaneda A; Kanai Y; Kyprianou N; Ikehara Y; Anzai N; Ichikawa T
Sci Rep; 2020 Jan; 10(1):1292. PubMed ID: 31992742
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Nagamori S; Promchan K; Nakajima T; Yamamoto N; Mori M; Kanai Y
Anticancer Res; 2010 Dec; 30(12):4819-28. PubMed ID: 21187458
[TBL] [Abstract][Full Text] [Related]
4. Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.
Ueno S; Kimura T; Yamaga T; Kawada A; Ochiai T; Endou H; Sakurai H
J Pharmacol Sci; 2016 Jun; 131(2):110-7. PubMed ID: 27262901
[TBL] [Abstract][Full Text] [Related]
5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
6. Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis.
Markowicz-Piasecka M; Huttunen J; Montaser A; Huttunen KM
Apoptosis; 2020 Jun; 25(5-6):426-440. PubMed ID: 32405891
[TBL] [Abstract][Full Text] [Related]
7. Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203.
Muto Y; Furihata T; Kaneko M; Higuchi K; Okunushi K; Morio H; Reien Y; Uesato M; Matsubara H; Anzai N
Anticancer Res; 2019 Jan; 39(1):159-165. PubMed ID: 30591453
[TBL] [Abstract][Full Text] [Related]
8. Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
Kaira K; Takahashi T; Murakami H; Shukuya T; Kenmotsu H; Naito T; Oriuchi N; Kanai Y; Endo M; Kondo H; Nakajima T; Yamamoto N
Anticancer Res; 2011 Nov; 31(11):3775-82. PubMed ID: 22110199
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma.
Cormerais Y; Pagnuzzi-Boncompagni M; Schrötter S; Giuliano S; Tambutté E; Endou H; Wempe MF; Pagès G; Pouysségur J; Picco V
J Cell Mol Med; 2019 Apr; 23(4):2711-2718. PubMed ID: 30784173
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
11. JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.
Okunushi K; Furihata T; Morio H; Muto Y; Higuchi K; Kaneko M; Otsuka Y; Ohno Y; Watanabe Y; Reien Y; Nakagawa K; Sakamoto S; Wakashin H; Shimojo N; Anzai N
J Pharmacol Sci; 2020 Sep; 144(1):16-22. PubMed ID: 32653341
[TBL] [Abstract][Full Text] [Related]
12. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.
Jung MJ; Rho JK; Kim YM; Jung JE; Jin YB; Ko YG; Lee JS; Lee SJ; Lee JC; Park MJ
Oncogene; 2013 Jan; 32(2):209-21. PubMed ID: 22370645
[TBL] [Abstract][Full Text] [Related]
15. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
[TBL] [Abstract][Full Text] [Related]
16. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
17. Induction of CTH expression in response to amino acid starvation confers resistance to anti-LAT1 therapy in MDA-MB-231 cells.
Yamaga T; Suehiro J; Wada Y; Sakurai H
Sci Rep; 2022 Jan; 12(1):1021. PubMed ID: 35046465
[TBL] [Abstract][Full Text] [Related]
18. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC.
Xie WB; Liang LH; Wu KG; Wang LX; He X; Song C; Wang YQ; Li YH
Cell Physiol Biochem; 2018; 46(2):654-663. PubMed ID: 29617683
[TBL] [Abstract][Full Text] [Related]
19. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.
Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L
EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931
[TBL] [Abstract][Full Text] [Related]
20. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model.
Häfliger P; Graff J; Rubin M; Stooss A; Dettmer MS; Altmann KH; Gertsch J; Charles RP
J Exp Clin Cancer Res; 2018 Sep; 37(1):234. PubMed ID: 30241549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
